Supplier Spotlight® highlights the unique skill sets and service offerings from organizations who are part of our CONNECTED COMMUNITY™. Below is an interview with Market Access & Pricing Strategy (MArS), the German-speaking market access experts. Tell us about MArS Market Access… Continue Reading
Consequential prescription drug pricing decisions in the United States increasingly involve high-stakes interactions between the manufacturer and the Institute for Clinical and Economic Review (ICER). Continue Reading
Written By: Americans spend more on prescription drugs than anyone else in the world. In a move to address this, CVS Caremark announced in August that it would allow self-funded insurers to exclude from their plan any drug launched at… Continue Reading
Written by Swarali Tadwalkar, MPH, Guest Blogger and Research Intern at HealthEconomics.Com Drug prices are the fastest-growing part of healthcare costs, and everyone – from patients, to physicians, policy-makers, and pharmaceutical companies – are grappling with price-setting and drug value assessment.… Continue Reading
Hardly a day goes by without a new article being published in the mainstream press or a medical journal discussing drug pricing. The cost of drugs is a hot potato topic at medical meetings, pharma conference rooms, government hearings, and… Continue Reading
